FDA tobacco regulator fired

The 1^er April 2025, Dr. Brian King, director of tobacco and other nicotine products regulation at the Food and Drug Administration (FDA), was removed from his position as part of a broad layoff and restructuring program at U.S. federal health agencies, resulting in the departure of many federal experts responsible for overseeing food safety, drug regulation, vaccine oversight, and nicotine-related products.

The move is part of a broader restructuring by the Trump administration that raises significant concerns about the future of public health policy and delivery in the United States.

Dismantling of the Tobacco Products Center division responsible for the application of texts

Brian King, director of the FDA's Center for Tobacco Products (CTP), which includes other nicotine products such as vaping products, has been relieved of his duties and offered a reassignment within the Indian Health Service.[1]The move follows a wave of layoffs that has hit the CTP more broadly: reports indicate that the entire tobacco enforcement division has been dismantled.

Dr. King, who previously led research on tobacco and new nicotine products at the CDC, has held that position since 2022. His departure marks a notable shift in federal tobacco control leadership as new nicotine products, including synthetic substitutes, continue to appear on the U.S. market.

The FDA is among the agencies within the Department of Health and Human Services affected by the restructuring. A total of 10,000 employees have been laid off, and another 10,000 have been offered early retirement or voluntary separation. The total workforce at the Department of Health and Human Services is expected to decline by nearly 25 percent, from 82,000 to about 62,000 employees. Among the affected agencies, the FDA has lost about 3,500 positions, the Centers for Disease Control and Prevention has lost 2,400 jobs, and the National Institutes of Health has canceled more than 230 grants, including those for HIV research.

Secretary of State Kennedy said the layoffs were necessary to move the Department of Health and Human Services away from "patient care" and adopts “a public health model that emphasizes prevention and reverses trends in chronic disease.” However, the restructuring has raised widespread concerns from health experts, lawmakers and advocacy groups.

Former FDA Commissioner Dr. Robert Califf warned of the long-term consequences of this restructuring "The FDA as we knew it is over, with most of the leadership with institutional knowledge and a deep understanding of product development and safety no longer employed."

Lawmakers, including Senators Bernie Sanders and Bill Cassidy, have asked the secretary of state to testify before Congress about the scope and rationale for the reorganization.

Impact on tobacco control and youth protection

The dismissal of Dr. Brian King and the dismantling of the enforcement division within the FDA's Center for Tobacco Products (CTP) come at a pivotal time for tobacco control efforts in the United States. These changes threaten to significantly reduce the federal government's ability to regulate and monitor an increasingly complex and rapidly evolving nicotine market.

Since its creation in 2009, the CTP has been responsible for implementing the Family Smoking Prevention and Tobacco Control Act, overseeing the regulation of a wide range of products, including cigarettes, e-cigarettes, cigars, oral nicotine products, and synthetic nicotine substitutes. Under Dr. King's leadership, the Center has paid particular attention to flavored vaping products and disposable e-cigarettes, which are particularly popular with teens and young adults.

Public health organizations have expressed deep concern that this sudden change in leadership, combined with the removal of enforcement personnel, could create a vacuum for the implementation and effectiveness of measures. The Campaign for Tobacco-Free Kids[2] warned that cuts to FDA and CDC tobacco control programs could pave the way for increased tobacco industry marketing, particularly to youth. Without adequate regulatory oversight, there is a growing risk that these products will circulate unchecked, increasing the likelihood of nicotine initiation among youth and other vulnerable groups. In addition, the loss of experienced regulatory staff may hamper the FDA's ability to review new product applications, monitor market trends, and enforce existing restrictions on illegally marketed products.

©Generation Without Tobacco

AE

[1] Matthew Perrone, FDA tobacco official is removed from post in latest blow to health agency's leadership, AP News, published April 1, 2025, accessed April 2, 2025

[2] Press release, Cuts to FDA and CDC Tobacco Programs Will Benefit Tobacco Industry at the Expense of Kids and Lives, CTFK, published April 1, 2025, accessed April 2, 2025